公开(公告)号：US20190269773A1

公开(公告)日：2019-09-05

申请号：US16348829

申请日：2017-11-09

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  PULMOTECT, INC. ,  THE TEXAS A&M UNIVERSITY SYSTEM

发明人： Burton F. DICKEY ,  Michael J. TUVIM ,  Scott E. Evans ,  Magnus HOOK ,  David P. HUSTON ,  Margarita MARTINEZ-MOCZYGEMBA ,  Brenton SCOTT

IPC分类号： A61K39/35 ,  A61K38/16 ,  C12N15/117 ,  A61K31/58 ,  A61P37/08

摘要： Embodiments are directed to methods and compositions for modulating an immune response. In certain aspects the immune response is a type I hypersensitivity response. In particular aspects the subject has allergic asthma or allergic rhinitis. Using a conventional experimental asthma mouse model (BALB/c), the inventors demonstrate that aerosol administration of TLR agonists, in particular a combination of TLR2/6 and TLR9 agonist (e.g., TLR9 oligonucleotide agonist/PAM2CSK4) along with an antigen (e.g., ovalbumin (OVA)) suppresses the immune response as exemplified by the production of antigen-specific IgE and decreases the number of airway eosinophils in bronchoalveolar lavage fluid (BAL) in response to intraperitoneal (IP) immunization with an antigen mixed with alum.

公开(公告)号：US20240033348A1

公开(公告)日：2024-02-01

申请号：US18484667

申请日：2023-10-11

申请人： THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  PULMOTECT, INC. ,  THE TEXAS A&M UNIVERSITY SYSTEM

发明人： Burton F. DICKEY ,  Michael J. TUVIM ,  Scott E. EVANS ,  Magnus HOOK ,  David P. HUSTON ,  Margarita MARTINEZ-MOCZYGEMBA ,  Brenton SCOTT

IPC分类号： A61K39/35 ,  A61P37/08 ,  A61K31/58 ,  A61K38/16 ,  C12N15/117 ,  H04B1/04 ,  H04B1/16 ,  H04B1/715 ,  H04B1/7156 ,  H04B1/40 ,  H04B1/713

CPC分类号： A61K39/35 ,  A61P37/08 ,  A61K31/58 ,  A61K38/164 ,  C12N15/117 ,  H04B1/04 ,  H04B1/16 ,  H04B1/715 ,  H04B1/7156 ,  H04B1/40 ,  H04B1/713 ,  A61K2039/55561

摘要： Certain embodiments are directed to compositions and methods for attenuating allergic responses in a subject.